AACR 2024
Interviews and expert commentary from AACR 2024 — study authors and key opinion leaders discuss the findings and their clinical implications.
Two Checkpoint Inhibitors in One Bispecific Molecule Improved Survival in Patients with High-Risk Gastric Cancer
An interview with: Jiafu Ji MD PhD DrPH FRCS, Fellow of the Chinese Academy of Medical Science, Professor and Chief, Gastrointestinal Cancer Center, Peking University Cancer Hospital, Beijing Institut
Exosome Liquid Biopsy for Earliest Pancreatic Cancer Detection
An interview with: Ajay Goel PhD, Chair of the Molecular Diagnostics and Experimental Therapeutics Department, Beckman Research Institute, City of Hope, Los Angeles California. SAN DIEGO—The prospect
Long Remissions with Bispecific T-cell Engager Antibody Therapy for Patients with Relapsed Multiple Myeloma
An interview with: Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology, Director of the Center of Excellence for Multiple Myeloma, Icahn School of Medicine, Mount Sinai, New
Olivier Lantz MD PhD; AACR 2024: Personalized Vaccine Brought Durable Immune Responses and Fewer Relapses in Head and Neck Cancers
An interview with: Olivier Lantz MD PhD, Head of the Clinical Immunology Laboratory, Institut Curie, Paris, France PARIS, France—A clinical trial using a personalized therapeutic vaccine, that